Novo Nordisk A/S $NVO Shares Sold by Allworth Financial LP

Key Points

• Allworth Financial LP cut its Novo Nordisk stake by 44.9% in the second quarter, selling 31,404 shares and retaining 38,586 shares valued at approximately $1.85 million.
• Novo Nordisk faces mixed investor sentiment: Wegovy’s approval for MASH in China and progress toward an oral Wegovy application offer growth opportunities, while concerns about the semaglutide patent cliff and a Morgan Stanley downgrade weigh on the stock.
• Shares opened at $43.03, near the lower end of their 12-month range, while analysts maintain a consensus “Hold” rating with a $64.94 price target; institutional investors own 11.54% of the company.

Allworth Financial LP decreased its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 44.9% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 38,586 shares of the company's stock after selling 31,404 shares during the quarter. Allworth Financial LP's holdings in Novo Nordisk A/S were worth $1,850,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Revolve Wealth Partners LLC lifted its stake in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after acquiring an additional 200 shares during the period. AQR Capital Management LLC raised its holdings in Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company's stock worth $4,312,000 after purchasing an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC lifted its position in Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company's stock worth $712,000 after purchasing an additional 1,587 shares during the period. Invesco Ltd. increased its position in shares of Novo Nordisk A/S by 26.3% during the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company's stock valued at $28,967,000 after purchasing an additional 87,467 shares during the period. Finally, Gamco Investors INC. ET AL bought a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth $314,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy received approval in China for MASH, making it the first GLP-1 receptor agonist in the country approved for the liver disease. The decision expands semaglutide’s potential beyond obesity and diabetes, although Novo has not provided a launch schedule or revenue outlook. Reuters article
• Positive Sentiment: China’s acceptance of Novo’s oral Wegovy application creates a potential avenue into the country’s growing GLP-1 weight-management market. Investors see the opportunity as a possible long-term growth driver, though regulatory approval, launch timing and competitive dynamics remain uncertain. Oral Wegovy China article
• Neutral Sentiment: HSBC raised its price target to 320 Danish kroner but kept a Hold rating, reflecting improved valuation expectations without a strong near-term conviction. HSBC price target article
• Positive Sentiment: Some analysts continue to view Novo’s valuation, strong margins, free cash flow and GLP-1 leadership as providing a margin of safety, suggesting the recent weakness may already reflect substantial execution and competitive risks. Novo Nordisk valuation analysis
• Negative Sentiment: The Morgan Stanley downgrade is the dominant near-term catalyst. Investors are questioning whether oral Wegovy, China expansion and other pipeline opportunities can replace revenue exposed to the semaglutide patent cliff, contributing to NVO’s decline and keeping sentiment weak. Morgan Stanley downgrade article

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Citigroup reissued a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Nordea Equity Research upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Friday, June 19th. BMO Capital Markets reissued a "market perform" rating and set a $47.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Deutsche Bank Aktiengesellschaft cut Novo Nordisk A/S from a "hold" rating to a "sell" rating in a report on Thursday, August 27th. Finally, Wall Street Zen lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, June 20th. Four analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $64.94.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $43.03 on Friday. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The stock has a market cap of $192.15 billion, a PE ratio of 10.52, a price-to-earnings-growth ratio of 1.48 and a beta of 0.74. The business has a fifty day simple moving average of $47.49 and a 200-day simple moving average of $43.65.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The firm had revenue of $11.98 billion for the quarter. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.45 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were issued a $0.5786 dividend. The ex-dividend date was Monday, August 17th. This represents a dividend yield of 258.0%. Novo Nordisk A/S's dividend payout ratio is currently 19.80%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.